Growing market ER-REBOA catheter adoption expanding beyond trauma into cardiac arrest, postpartum hemorrhage, interventional radiology, perioperative care, and pre-hospital settings, indicating multiple high-potential verticals for cross-selling and product expansion.

Geographic expansion Device already approved in the US, Europe, and Canada with usage exceeding 250 hospitals; opportunities exist to accelerate penetration in international markets and expand to additional regions with established trauma and emergency medicine networks.

New product line Recent launches including pREBOA-PRO enabling True Partial REBOA suggest upsell and add-on strategies for hospitals seeking to extend aortic occlusion window, offering higher-value capabilities to current customers.

Executive momentum Strategic hires across commercialization and advisory leadership, including Chief Commercial Officer and Clinical Advisory Board, signaling strengthened sales execution, training programs, and clinician-aligned messaging for larger deals.

Public credibility Historical 510(k) clearance, military-origin innovation, significant media coverage, and ongoing press announcements enhance credibility with procurement and trauma centers, supporting contract opportunities and faster evaluation cycles.